

## AGM Results

**Melbourne, Australia; 29 November 2022:** Starpharma Holdings Limited (ASX: SPL, OTCQX:SPHRY) advises details of the resolutions and the proxies and votes received in respect of each resolution at its AGM today in accordance with ASX Listing Rule 3.13.2 and section 251AA of the Corporations Act, as set out in the attached proxy and voting summary.

### About Starpharma

Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a global biopharmaceutical company and a world leader in the development of new pharmaceutical and medical products based on proprietary polymers called dendrimers, with programs for DEP<sup>®</sup> drug delivery, respiratory viruses and VivaGel<sup>®</sup>.

Starpharma's proprietary drug delivery platform technology, DEP<sup>®</sup>, is being used to improve pharmaceuticals, to reduce toxicities and enhance their performance. There are numerous internal and partnered programs underway to develop DEP<sup>®</sup> versions of existing drugs, particularly in the area of anti-cancer therapies.

DEP<sup>®</sup> partnerships include oncology programs with AstraZeneca, with MSD in the area of Antibody Drug Conjugates (ADCs), with Chase Sun in the area of anti-infectives and other world leading pharmaceutical companies. Partnered DEP<sup>®</sup> programs have the potential to generate significant future milestones and royalties.

Starpharma has developed VIRALEZE<sup>™</sup>, an antiviral nasal spray that is registered in a number of countries, including in Europe and the UK. VIRALEZE<sup>™</sup> is not approved for use or supply in Australia. SPL7013 is also utilised in the following products - VivaGel<sup>®</sup> condom and VivaGel<sup>®</sup> BV. VivaGel<sup>®</sup> products have been licensed in >160 countries and are registered in >45 countries, including the UK, Europe, Japan, Southeast Asia, South Africa, Australia and New Zealand.

[Starpharma.com](https://www.starpharma.com) | [Twitter](https://twitter.com/starpharma) | [LinkedIn](https://www.linkedin.com/company/starpharma)

### Media: Sumit Media

Grant Titmus  
Mob: +61 419 388 161  
[grant@sumitmedia.com.au](mailto:grant@sumitmedia.com.au)

### Starpharma Holdings Limited

Dr Jackie Fairley, Chief Executive Officer  
Nigel Baade, CFO and Company Secretary  
+61 3 8532 2704  
[investor.relations@starpharma.com](mailto:investor.relations@starpharma.com)  
4-6 Southampton Crescent  
Abbotsford Vic 3067

### Disclosure

This ASX Announcement was authorised for release by the Company Secretary, Mr Nigel Baade.

### Forward Looking Statements

This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", "outlook", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise. Clinical case studies and other clinical information given in this document are given for illustrative purposes only and are not necessarily a guide to product performance and no representation or warranty is made by any person as to the likelihood of achievement or reasonableness of future results. Nothing contained in this document nor any information made available to you is, or shall be relied upon as, a promise, representation, warranty or guarantee as to the past, present or the future performance of any Starpharma product.

For personal use only

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried
1 Adoption of Remuneration Report	Ordinary	213,951,056 89.63%	24,026,485 10.06%	736,061 0.31%	5,854,797	215,487,980 89.73%	24,653,921 10.27%	6,014,797	Carried
2 Re-elect Board endorsed Director - Dr Jeff Davies	Ordinary	247,541,878 99.11%	1,113,210 0.44%	1,126,061 0.45%	441,282	251,210,154 99.55%	1,129,670 0.45%	833,985	Carried
3 Approve Performance Rights to Dr Jacinth Fairley	Ordinary	211,978,916 88.53%	26,139,035 10.92%	1,322,813 0.55%	9,815,427	213,890,979 88.32%	28,292,460 11.68%	9,914,130	Carried
4 Election of non-Board endorsed candidate	Ordinary	40,117,285 16.08%	208,511,121 83.61%	753,845 0.31%	840,180	44,077,907 17.44%	208,656,909 82.56%	978,320	Not Carried

\* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.

For personal use only